Temporary disablement feature for implantable device with anti-tachyarrhythmia functions
An implantable cardiac rhythm management device for delivering anti-tachyarrhythmia therapy is provided with a temporary disablement feature so that the delivery of anti-tachyarrhythmia therapy may be conveniently disabled and re-enabled. The feature is particularly useful to patients who are undergoing imaging procedures or surgical procedures where electro-cauterizing instruments may cause inadvertent triggering of cardioversion/defibrillation shocks and/or anti-tachycardia pacing.
1. An implantable cardiac rhythm management device, comprising:
a sensing channel for sensing an electrogram signal representing cardiac electrical activity and circuitry for generating a chamber sense when the electrogram signal exceeds a specified threshold;
one or more stimulation channels for delivering electrical stimulation to a subject's heart;
an activity sensor for measuring an activity level;
a controller programmed to detect a tachyarrhythmia from the rate at which chamber senses are generated and to cause delivery of anti-tachyarrhythmia therapy through one or more of the stimulation channels upon detection of a tachyarrhythmia;
a telemetry interface by which the controller may communicate with an external device;
wherein the controller is programmed to disable the delivery of anti-tachyarrhythmia therapy for a specified time interval upon receipt of a temporary suspend command from the external device via the telemetry interface and to re-enable the delivery of anti-tachyarrhythmia therapy upon expiration of the specified time interval; and,
wherein the controller is programmed to re-enable delivery of anti-tachyarrhythmia therapy before expiration of the specified time interval upon measurement of an activity level above a specified threshold value.
2. The device of claim 1 wherein the specified time interval for which the delivery of anti-tachyarrhythmia therapy is disabled is communicated to the implantable device by the external device via the telemetry interface.
3. The device of claim 1 wherein delivery of anti-tachyarrhythmia therapy is re-enabled before expiration of the specified time interval by receipt of a resume command from the external device via the telemetry interface.
4. The device of claim 1 further comprising a magnetic switch actuated by application of a magnetic field and wherein delivery of anti-tachyarrhythmia therapy is re-enabled before expiration of the specified time interval by actuation of the magnetic switch.
5. The device of claim 1 wherein the controller is further programmed to disable the delivery of anti-tachyarrhythmia therapy indefinitely upon receipt of an indefinite suspend command from the external device via the telemetry interface and to re-enable the delivery of anti-tachyarrhythmia therapy upon receipt of a resume command.
6. The device of claim 5 further comprising a magnetic switch actuated by application of a magnetic field and wherein the resume command is communicated to the implantable device by actuation of the magnetic switch.
7. The device of claim 5 wherein the resume command is generated upon measurement of an activity level above a specified threshold value.
8. The device of claim 1 further comprising a magnetic switch actuated by application of a magnetic field and wherein the controller is further programmed to disable the delivery of anti-tachyarrhythmia therapy indefinitely upon receipt of an indefinite suspend with magnetic re-enable command from the external device and to re-enable the delivery of anti-tachyarrhythmia therapy upon actuation of the magnetic switch.
9. The device of claim 1 wherein the one or more stimulation channels include a pacing channel for delivering anti-tachycardia pacing and wherein the controller is programmed to cause delivery of anti-tachyarrhythmia therapy in the form of anti-tachycardia pacing upon detection of a tachyarrhythmia.
10. The device of claim 1 wherein the one or more stimulation channels include a shock channel for delivering cardioversion/defibrillation shocks and wherein the controller is programmed to cause delivery of anti-tachyarrhythmia therapy in the form of a cardioversion/defibrillation shock upon detection of a tachyarrhythmia.
11. The device of claim 1 wherein the one or more stimulation channels include a pacing channel for delivering anti-tachycardia pacing and a shock channel for delivering cardioversion/defibrillation shocks, and wherein the controller is programmed to cause delivery of anti-tachyarrhythmia therapy in the form of anti-tachycardia pacing upon detection of a tachyarrhythmia in a tachycardia zone and in the form of a cardioversion/defibrillation shock upon detection of a tachyarrhythmia in a fibrillation zone.
12. The device of claim 1 wherein the controller is programmed to disable anti-tachyarrhythmia therapy by disabling one or more sensing channels.
13. The device of claim 1 wherein the one or more stimulation channels include a pacing channel for delivering bradycardia pacing in an inhibited demand mode and further wherein the controller is programmed to disable anti-tachyarrhythmia therapy by disabling one or more sensing channels which thereby also causes the device to revert to an asynchronous pacing mode.
14. An implantable cardiac rhythm management device, comprising:
a sensing channel for sensing an electrogram signal representing cardiac electrical activity and circuitry for generating a chamber sense when the electrogram signal exceeds a specified threshold;
one or more stimulation channels for delivering electrical stimulation to a subject's heart;
a controller programmed to detect a tachyarrhythmia from the rate at which chamber senses are generated and to cause delivery of anti-tachyarrhythmia therapy through one or more of the stimulation channels upon detection of a tachyarrhythmia;
a magnetic switch interfaced to the controller which is actuated by application of a magnetic field;
a telemetry interface by which the controller may communicate with an external device; and,
wherein the controller is programmed to disable the delivery of anti-tachyarrhythmia therapy indefinitely upon receipt of an indefinite suspend with magnetic re-enable command from the external device and to re-enable the delivery of anti-tachyarrhythmia therapy upon actuation of the magnetic switch.
15. The device of claim 14 wherein the controller is programmed to disable the delivery of anti-tachyarrhythmia therapy for a specified time interval upon receipt of a temporary suspend command from the external device via the telemetry interface and to re-enable the delivery of anti-tachyarrhythmia therapy upon expiration of the specified time interval.
16. The device of claim 15 wherein the controller is programmed to re-enable delivery of anti-tachyarrhythmia therapy before expiration of the specified time interval by actuation of the magnetic switch.
17. The device of claim 14 wherein the one or more stimulation channels include a pacing channel for delivering bradycardia pacing in an inhibited demand mode and further wherein the controller is programmed to disable anti-tachyarrhythmia therapy by disabling the sensing channel which thereby also causes the device to revert to an asynchronous pacing mode.
18. An implantable cardiac rhythm management device, comprising:
a sensing channel for sensing an electrogram signal representing cardiac electrical activity and circuitry for generating a chamber sense when the electrogram signal exceeds a specified threshold;
one or more stimulation channels for delivering electrical stimulation to a subject's heart;
a controller programmed to detect a tachyarrhythmia from the rate at which chamber senses are generated and to cause delivery of anti-tachyarrhythmia therapy through one or more of the stimulation channels upon detection of a tachyarrhythmia;
an activity sensor interfaced to the controller for measuring an activity level;
a telemetry interface by which the controller may communicate with an external device; and,
wherein the controller is programmed to disable the delivery of the anti-tachyarrhythmia therapy indefinitely upon receipt of an indefinite suspend with activity re-enable command from the external device and to re-enable the delivery of anti-tachyarrhythmia therapy upon measurement of an activity level above a specified threshold value.
19. The device of claim 18 wherein the one or more stimulation channels include a pacing channel for delivering bradycardia pacing in an inhibited demand mode and further wherein the controller is programmed to disable anti-tachyarrhythmia therapy by disabling the sensing channel which thereby also causes the device to revert to an asynchronous pacing mode.
20. The device of claim 18 further comprising a magnetic switch interfaced to the controller which is actuated by application of a magnetic field and wherein the controller is programmed to re-enable delivery of anti-tachyarrhythmia therapy by actuation of the magnetic switch.